Inauhzin is an inhibitor of SIRT1 that activates p53; it also inhibits inosine monophosphate dehydrogenase (IMPDH). Inauhzin exhibits anticancer chemotherapeutic activities, inducing apoptosis and suppressing cell growth in non-small cell lung cancer (NSCLC) and colon cancer cells. This compound also induces senescence in and represses tumor growth in cellular and animal models of lung cancer and colon carcinoma.
| Cas No. | 309271-94-1 |
|---|---|
| Purity | ≥98% |
| Formula | C25H19N5OS2 |
| Formula Wt. | 469.58 |
| IUPAC Name | 1-(10H-Phenothiazin-10-yl)-2-(5H-[1,2,4]triazino[5,6-b]indol-3-ylsulfanyl)-1-butanone |
| Synonym | INZ |
| Solubility | DMSO: 21 mg/mL |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Zhang Q, Zhou X, Wu R, et al. The role of IMP dehydrogenase 2 in Inauhzin-induced ribosomal stress. Elife. 2014 Oct 27;3. PMID: 25347121.
Zhang Y, Zhang Q, Zeng SX, et al. Inauhzin sensitizes p53-dependent cytotoxicity and tumor suppression of chemotherapeutic agents. Neoplasia. 2013 May;15(5):523-34. PMID: 23633924.
